TW200303219A - Tablets having improved tabletting characteristics and process for producing the same - Google Patents

Tablets having improved tabletting characteristics and process for producing the same Download PDF

Info

Publication number
TW200303219A
TW200303219A TW092102910A TW92102910A TW200303219A TW 200303219 A TW200303219 A TW 200303219A TW 092102910 A TW092102910 A TW 092102910A TW 92102910 A TW92102910 A TW 92102910A TW 200303219 A TW200303219 A TW 200303219A
Authority
TW
Taiwan
Prior art keywords
weight
tablet
mixture
tablets
added
Prior art date
Application number
TW092102910A
Other languages
Chinese (zh)
Inventor
Shunichi Kawasaki
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of TW200303219A publication Critical patent/TW200303219A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Abstract

It is intended to provide tablets which have a favorable texture in taking and excellent tabletting characteristics, abrasion resistance and mechanical strength. Tablets which are produced by blending a powdery or granular mixture comprising (1) an effective amount of a pharmacologically active substance and (2) 50% by weight or more of a water-soluble filler with (3) a tabletting characteristic improving agent containing moisture at least in an amount corresponding to the equilibrated moisture content at 25 DEG C under a humidity of 12% and having an average grain size of 100 μ m or less, at a ratio of 1 to 50 % by weight based on the above mixture, and then tabletting the resultant mixture.

Description

200303219 (1) 玖、發明說明 【發明所屬之技術領域】 本發明係關於一種壓片性被 法,特別是一種口腔內崩解片及 【先前技術】 口腔內崩解片係因於口腔內 高齡者等之不易服用片劑者亦易 崩解片係因於口腔內崩解,故期 粗糙感等之服用感優異者。因此 之糖、糖醇等之水溶性賦形劑之 感。 例如,於W093/1 2769號公 中揭示出將藥理活性成分之溶液 後,使其凍結乾燥、送風乾燥或 。又,其口腔內崩解片係缺乏機 PTP包裝取出時無法避免該崩解 特開平5 - 271〇54號公報中 分、糖類及該糖類之粒子表面濕 錠之口腔內崩解劑。其崩解劑係 粒子表面,進行混合物之水分調 前之混合物調整爲均勻之水份量 極端低下之濕潤混合物塡充於打 物附著且殘留於打錠機內部,而 改善之片劑及其製造之方 其製造方法。 迅速崩解,故即使幼兒、 於服用之片劑。其口腔內 望開發出崩解後之味道、 ,通常提高添加於崩解片 比例可提升崩解片之服用 報及W094/12 1 42號公報 或懸濁液塡充於成形袋子 減壓乾燥之口腔內崩解錠 械強度,故將該崩解片由 片之彪損。 揭示出將含有藥理活性成 潤程度之水分的混合物打 於打錠前添加水於糖類之 整後以製造。又,將打錠 係極爲困難。又,流動性 錠機,故應避免濕潤混合 塡充時,濕潤混合物之塡 -5- (2) (2)200303219 充量產生不均勻。又’該公報之方法係必須將打錠後將片 劑乾燥作爲必要步驟。 於W093/203 80號公報中揭示出含有成形性低之糖醇 及成形性局之糖醇的崩解片。又,糖醇之含有量高時,產 生覆蓋物等之打錠阻礙等之缺點。因此,該公報之崩解片 係不具備可滿足程度之壓片性。 使用糖、糖醇等之缺乏成形性的水溶性賦形劑且提高 其含有比例,可提升片劑之服用感,而含有比例高時,則 缺乏壓片性係如以上所述。 片劑之服用感佳且壓片性優異之片劑係並未開發出。 故期望開發出可一倂解決提昇片劑之服用感與提昇壓片性 之兩者相反的方法且簡便且生產性佳之片劑。 【發明內容】 本發明係以提供一種片劑之服用感良好且壓片性、耐 摩損性及機械強度優異之片劑作爲目的。 本發明係以提供一種易於片劑化之具有充分的壓片性 、耐摩損性及機械強度且於口腔內快速崩解所得之口腔內 崩解錠作爲目的。 本發明者們欲解決上述之問題而專心硏究之結果,於 添加多量水溶性賦形劑之醫藥製劑中,添加特定比例之具 有特定量水份之壓片性改善劑時,可解決該問題。本發明 係基於此種之知見以完成。 1. 一種片劑,其特徵爲於含有(1)有效量之藥理活性 -6- (3) (3)200303219 物質及(2)5 0重量%以上之水溶性賦形劑之粉狀或顆粒狀 混合物中,將(3 )具有溫度2 5 °C、溼度1 2 %之平衡水份以 上之水份,且平均粒徑爲1 〇〇 # m以下之壓片性改善劑, 對於該混合物以1〜5 0重量%之比例添加且壓片製得。 2. —種片劑之製造方法,其特徵爲於含有(1)有效量 之藥理活性物質及(2) 5 0重量%以上之水溶性賦形劑之粉 狀或顆粒狀混合物中,將(3)具有溫度25°C、溼度12%之 平衡水份以上之水份,且平均粒徑爲1 〇〇 // m以下之壓片 性改善劑,對於該混合物以1〜5 0重量%之比例添加且壓 片者。 3. —種口內崩解片,其特徵爲於含有(1)有效量之藥 理活性物質及(2)50重量%以上之水溶性賦形劑之粉狀或 顆粒狀混合物中,將(3 )具有溫度2 5 °C、溼度1 2 %之平衡 水分以上之水份,且平均粒徑爲1 0 0 // m以下之壓片性改 善劑,對於該混合物以1〜5 0重量%之比例添加且壓片製 得。 4. 一種口內崩解片之製造方法,其特徵爲於含有 (1)有效量之藥理活性物質及 (2)50重量%以上之水溶性 賦形劑之粉狀或顆粒狀混合物中,將(3)具有溫度25 °C、 溼度1 2 %之平衡水份以上之水份,且平均粒徑爲1 〇 〇 # m 以下之壓片性改善劑,對於該混合物以1〜50重量%之比 例添加且壓片者。 欲實施本發明之最佳形態 -7- (4) (4)200303219 本發明之片劑係於含有藥理活性物質及水溶性賦形劑 之粉狀或顆粒狀混合物中,添加特定之壓片性改善劑且經 由壓片所製得。 首先’對於粉狀或顆粒狀混合物說明之。 藥理活性物質係可廣泛使用公知者。此種藥理性物質 係可舉例如呼吸器用製劑、消化器用製劑、循環器官用製 劑、中樞神經用製劑、末梢神經用製劑、抗生物質用製劑 、化學療法劑、抗腫瘤劑、血小板凝結抑制劑、抗過敏劑 、維他命劑之各種製劑所添加之一般的藥理性物質。其具 體例係例如茶鹼、西洛他坐片(Cilostaz〇1)、瑞巴氟沙星 (Rrepafloxacia)、卡替洛爾(Carte〇1〇1)、丙卡特羅 (procaterol)、瑞巴匹特(Rebaniipid)、aripiprazol 等。而 粉狀或顆粒狀混合物係可添加有效量之藥理活性物質。 水溶性賦形劑係可廣泛使用公知者,例如可舉例爲糖 、糖醇、水溶性高分子物質、洋菜膠等。 作爲糖,具體而言係可舉例如葡萄糖、果糖、白糖等 之單糖、麥芽糖、乳糖、蔗糖、海藻糖等之寡糖。 作爲糖醇’具體而言係可舉例如甘露糖醇、山梨糖醇 、麥芽糖醇、赤鮮醇、木糖醇等。 溶性高分子物質’具體而言係可舉例如聚乙二醇〔 microgol(商品名)〕、聚丙基二醇等。 此些水溶性賦形劑係可使用單獨1種或混合2種以上 〇 該水溶性賦形劑之中,最佳爲糖醇。 -8- (5) (5)200303219 粉狀或顆粒狀混合物中之該水溶性賦之含有量,一般 爲50重量%以上,最佳爲6〇〜9〇重量%,最佳爲7〇〜 99重量%。 該粉狀或顆粒狀混合物中,除藥理活性物質及水溶性 賦形劑之外,必要時可適當含有其他之添加劑。此種添加 劑係可舉例如香料、甘味劑等。 香料係可舉例如澄萃取物、澄油、留香蘭油、薄荷油 、香子蘭香料、檸檬油、1 -薄荷醇等。甜味劑係可舉例 如阿斯巴甜、糖精鈉、甜味茶、甘草末、甘油、蜂蜜、水 貽等。 此些添加劑係可使用單獨1種或混合2種以上。 含有藥理性物質及水溶性賦形劑之混合物,最佳爲顆 粒狀者。 顆粒狀混合物係例如混合藥理活性物質及水溶性賦形 d且將製得之粉狀混合物經造粒而製造。造粒係可經由公 知方法,例如濕式法、乾式法進行。 製造本發明之片劑時,可使用具有溫度2 5 °c、濕度 1 2 %之平衡水份以上之水份之壓片性改善劑。 作爲具有溫度2 5 C、溼度1 2 %之平衡水份以上之水 份,且其平均粒徑爲1 〇〇 # m以下之壓片性改善劑係可舉 例如澱粉類、纖維素類、高分子物質且具備該要點。 澱粉類係例如小麥澱粉、米澱粉、玉米澱粉、馬鈴馨 澱粉、糊精、α化澱粉、部份α化澱粉、羥基丙基潑粉、 竣基甲基殿粉、α -環糊精' /3 -環糊精、1,3 - /3 -葡聚伊等 -9- (6) (6)200303219 纖維素類係可舉例如結晶纖維素、羥基丙基纖維素、 低取代度羥基丙基纖維素、羥基丙基甲基纖維素、羧甲基 、殘甲基纖維素鈣、羧甲基纖維素鈉、交聯羧甲基纖維鈉 等。 高分子物質係可舉例如聚乙烯基比各烷酮、聚乙烯醇 等之合成高分子物質 '洋菜膠、明膠等之天然高分子物質 〇 此些之壓片性改善劑中,最佳爲玉米澱粉、馬鈴薯澱 粉、結晶纖維素、低取代度羥基丙基纖維素、聚乙烯比各 烷酮等。 溫度2 5 °C、溼度1 2 %之平衡水份係依壓片性改善劑 之種類而相異。 溫度2 5 °C、溼度1 2 %之平衡水份係例如玉米澱粉爲 約5.3 % ’馬鈴薯源粉係約1 5 %,部分α化澱粉爲4 %, 結晶纖維係約2.3〜2.5%,低取代羥基丙基纖維素係約 3 . 〇〜3 . 1 %,聚乙烯比各同係約3 . 5〜3 . 8 %。 本發明中溫度2 5 °C、溼度1 2 %之平衡水份係將各化 合物放入加入有氯化鋰之飽和水溶液之乾燥器中,且將於 2 5 °C放置48小時後之水份,使用容量法卡式水份計(商品 名:KF - 〇 6、三菱化學(股份有限公司)製作)而測定之値 〇 粒子徑係例如玉米澱粉約爲2〜3 2 // m,馬鈴薯澱粉 係約7 〇〜9 0 // m,部分α化丨殿粉係約7 0 # m (平均直),結 -10- (7) (7)200303219 晶纖維係約1 7〜40 // m,低取代羥基丙基纖維素係約25 〜50//m,聚乙烯比各同係30〜75/zm。 此些壓片性改善劑係可使用單獨1種或混合2種以上 〇 壓片性改善劑之添加量對於含有藥理活性物質及水溶 性賦形劑之粉狀或顆粒狀混合物,通常爲1重量%以上, 最佳爲2〜50重量%,更佳爲5〜20重量%。 本發明片劑係於含有藥理活性物質及水溶性賦形劑之 混合物中,添加特定量該特定之壓片劑改善劑,接者將製 得之添加物經由片劑化製造者。 片劑化時,可廣泛使用公知之片劑化方法。因爲製造 片劑化之裝置係以往之經口製劑的製劑之一般使用之裝置 爲佳,故不需爲特別的製造裝置。 經由添加該特定之壓片性改善劑之壓片性被改善,故 片劑成形時,不產生覆蓋物等打錠阻礙、片劑硬度不足等 之不佳情況。其結果,不必使用特殊之製造裝置,使用一 般之片劑製造裝置即可製造本發明之片劑。 本發明片劑係具備充分之耐摩損性及機械強度’因此 ,不引起實際上PTP之包裝作業時及開封時之破損。 本發明片劑係因於口腔內快速崩解或溶解’故爲幼兒 、高齡者極容意於服用。 【實施方式】 實施例 -11 - (8) (8)200303219 以下,舉出實施例及比較例更進一步淸楚地說明本發 明。又,以下使用之壓片性改善劑之詳細係如以下所述。 各種壓片性改善劑中之水份係使用容量法卡式水份計測定 〇 玉米澱粉:日本食品加工(股份有限公司)製作、粒子徑 2〜3 2 // m、於溫度2 5 °C,溼度1 2 %保存4 8小時後之平衡 水份5 . 3 % 馬鈴薯:日澱化學(股份有限公司)製作、粒子徑70〜 90 // m、於溫度25°C,溼度I2%保存48小時後之平衡水 份 1.5% 阿比賽魯PH — F2〇(商品名):結晶纖維素、旭化成(股 份有限公司)製作、平均粒子徑1 7 // m、於溫度2 5 °C,溼度 1 2 %保存4 8小時後之平衡水份2.5 % 阿比賽魯PH — 301 (商品名):結晶纖維素、旭化成(股 份有限公司)製作、平均粒子徑4 0 // m、於溫度2 5 °C,溼度 1 2 %保存4 8小時後之平衡水份2.3 % LH- 3 1 :低取代度羥基丙基纖維素、信越化學(股份有 限公司)製作、平均粒子徑2 5 // m、於溫度2 5 °C ,溼度1 2 %保存4 8小時後之平衡水份3 . 1 % LH - 1 1 :低取代度羥基丙基纖維素、信越化學(股份有 限公司)製作、平均粒子徑5 0 // m、於溫度2 5 °C,溼度1 2 %保存4 8小時後之平衡水份3 . 〇 % PVP (XL — 10):聚丙基比各烷酮 '日本ISP(股份有限 公司)製作、平均粒子徑3 0厂m、於溫度2 5 °C,溼度]2 % -12- 200303219 Ο) 保存4 8小時後之平衡水份5.8 % PVP(XL):聚丙基比各烷酮、日本ISP(股份有限公司) 製作、平均粒子徑7 5 // m、於溫度2 5 °C,溼度1 2 %保存4 8 小時後之平衡水份3 . 5 % 富基卡林S G(商品名):磷酸鈣、富士化學工業(股份有 限公司)製作、平均粒子徑1 13 // m、於溫度25°C,溼度12 %保存48小時後之平衡水份0.9% 車乙處理(於真空3小時以上加熱至8〇°c)該各種壓片 性改善劑而製得調整品A。 又,加濕處理(於溫度25°C,溼度6〇%放置24小時以 上)該各種壓片性改善劑而製得調整品D。又,混合調整 品A與調整品D製得調整品B及調整品c。此些調整品 之水份總結表示如表1。200303219 (1) 发明. Description of the invention [Technical field to which the invention belongs] The present invention relates to a tablet compression method, in particular to an orally disintegrating tablet and [prior art] The intraoral disintegrating tablet is due to the advanced age in the oral cavity Those who are not easy to take tablets and also easily disintegrate tablets are those who have excellent feeling of taking such as rough feeling due to disintegration in the oral cavity. Therefore, the sugar, sugar alcohol and the like are water-soluble excipients. For example, in W093 / 1 2769, the solution of a pharmacologically active ingredient is freeze-dried, air-dried or dried. In addition, its intraoral disintegrating tablet lacks organic PTP packaging, and the disintegration is unavoidable when it is taken out of Japanese Unexamined Patent Publication No. 5-271054, orally, a disintegrating agent for wet tablets on the surface of sugars and sugar particles. The disintegrating agent is on the particle surface, and the mixture before adjusting the moisture content of the mixture is adjusted to a uniform wet mixture with extremely low water content. It is filled in the object and remains in the tablet machine, and the improved tablet and its manufacturing方 其 Manufacture method. Disintegrates quickly, so even young children, taking tablets. The oral cavity is expected to develop a disintegrated taste. Usually, increasing the proportion of disintegrating tablets can increase the disintegrating tablets and the publication No. W094 / 12 1 42 or the suspension is filled in a formed bag and dried under reduced pressure. The strength of the disintegrating tablet in the oral cavity is such that the disintegrating tablet is damaged by the tablet. It was revealed that a mixture containing water having a pharmacologically active degree of moistening was added to the sugar before the tableting, and the whole sugar was added to make it. In addition, it is extremely difficult to make a spindle. In addition, the fluidity of the spindle should be avoided. When the wet mixture is filled, the filling of the wet mixture will be uneven. -5- (2) (2) 200303219 The method of this publication requires that the tablets be dried after tabletting as a necessary step. In W093 / 203 80, a disintegrating tablet containing sugar alcohol having low moldability and sugar alcohol having moldability is disclosed. In addition, when the sugar alcohol content is high, there are disadvantages such as hindering tableting of coatings and the like. Therefore, the disintegrating tablets of this publication do not have a satisfactory degree of tabletability. The use of sugars, sugar alcohols, and other water-soluble excipients lacking moldability and increasing their content ratio can improve the tablet's feeling of taking. When the content ratio is high, the lack of tabletability is as described above. Tablets with good tablet feel and excellent tabletability have not been developed. Therefore, it has been desired to develop a tablet that can solve both the problem of improving the feeling of taking a tablet and improving the tabletability, and that is simple and has high productivity. [Summary of the Invention] The present invention aims to provide a tablet having a good feeling of taking a tablet and excellent tableting properties, abrasion resistance, and mechanical strength. The present invention aims to provide an orally disintegrating tablet which is easy to be tableted, has sufficient tabletability, abrasion resistance, and mechanical strength, and is rapidly disintegrated in the oral cavity. As a result of the intent of the present inventors to solve the above-mentioned problems, when a large amount of water-soluble excipients are added to a pharmaceutical preparation, when a specific ratio of a tableting improver having a specific amount of water is added, the problem can be solved. . The present invention has been completed based on such knowledge. 1. A tablet, characterized by powder or granules containing (1) an effective amount of pharmacological activity-6- (3) (3) 200303219 substance and (2) 50% by weight or more of water-soluble excipients In the mixture, (3) a tabletability improver having an equilibrium moisture of a temperature of 25 ° C and a humidity of 12% or more and an average particle diameter of 100 #m or less, and for the mixture, 1 to 50% by weight is added and tabletted. 2. —A method for manufacturing a tablet, characterized in that in a powdery or granular mixture containing (1) an effective amount of a pharmacologically active substance and (2) 50% by weight or more of a water-soluble excipient, ( 3) A tableting improver having a moisture of more than equilibrium moisture at a temperature of 25 ° C and a humidity of 12%, and an average particle diameter of 1000 // m or less, and 1 to 50% by weight of the mixture. Proportions added and compressed. 3. —Intra-oral disintegrating tablet, characterized in that (3) a powdery or granular mixture containing (1) an effective amount of a pharmacologically active substance and (2) 50% by weight or more of a water-soluble excipient, (3 ) A tableting improver with a moisture content above the equilibrium moisture of 25 ° C and a humidity of 12% and an average particle size of 1 0 0 // m or less, for the mixture at 1 to 50% by weight Proportionally added and compressed. 4. A method for manufacturing an orally disintegrating tablet, characterized in that it is mixed in a powdery or granular form containing (1) an effective amount of a pharmacologically active substance and (2) 50% by weight or more of a water-soluble excipient, (3) A tableting improver having a moisture content of 25 ° C or more and a moisture balance of 12% or more, and an average particle size of 100 # m or less, and 1 to 50% by weight of the mixture. Proportions added and compressed. The best form to implement the present invention-7- (4) (4) 200303219 The tablet of the present invention is a powdery or granular mixture containing a pharmacologically active substance and a water-soluble excipient, and a specific tabletting property is added Improver and made by tabletting. First, a description is given of a powdery or granular mixture. Pharmacologically active substances are widely known. Examples of such pharmacological substances include preparations for respirators, preparations for digestive organs, preparations for circulatory organs, preparations for central nerves, preparations for peripheral nerves, preparations for antibiotics, chemotherapeutics, antitumor agents, platelet coagulation inhibitors, and antibacterial agents. General pharmacological substances added to various preparations of allergens and vitamins. Specific examples thereof are, for example, theophylline, cilostaz 〇1, Rrepafloxacia, Carteol 010, procaterol, ribapi (Rebaniipid), aripiprazol, etc. And powdery or granular mixtures can be added with effective amounts of pharmacologically active substances. Water-soluble excipients are widely known, and examples thereof include sugars, sugar alcohols, water-soluble polymer substances, and agar gum. Specific examples of the sugar include monosaccharides such as glucose, fructose, and sugar, and oligosaccharides such as maltose, lactose, sucrose, and trehalose. Specific examples of the sugar alcohol 'include mannitol, sorbitol, maltitol, erythritol, and xylitol. Specific examples of the soluble polymer substance 'include polyethylene glycol [microgol (trade name)], and polypropylene glycol. These water-soluble excipients can be used singly or in combination of two or more kinds. Among the water-soluble excipients, sugar alcohols are most preferred. -8- (5) (5) 200303219 The content of the water-soluble ingredient in the powdery or granular mixture is generally 50% by weight or more, preferably 60 to 90% by weight, and most preferably 70% to 99% by weight. The powdery or granular mixture may suitably contain other additives in addition to the pharmacologically active substance and the water-soluble excipient, if necessary. Examples of such additives include spices and sweeteners. Examples of the fragrance system include clear extract, clear oil, vanilla oil, peppermint oil, vanilla fragrance, lemon oil, 1-menthol, and the like. Examples of sweeteners include aspartame, sodium saccharin, sweet tea, licorice, glycerin, honey, water mussel and the like. These additives may be used alone or in combination of two or more. Mixtures containing pharmacological substances and water-soluble excipients, preferably granules. The granular mixture is produced by, for example, mixing a pharmacologically active substance and a water-soluble excipient d and granulating the obtained powdery mixture. The granulation system can be performed by a known method such as a wet method and a dry method. When manufacturing the tablet of the present invention, a tableting improver having a moisture content of a balance moisture of 25 ° C or higher and a humidity of 12% or higher can be used. Examples of the tabletability improving agent having a moisture balance of 2 5 C and a humidity of 12% or more and an average particle diameter of 100 # m or less include starch, cellulose, and high Molecular substances have this point. Starch types such as wheat starch, rice starch, corn starch, maltese starch, dextrin, α-starch, partially α-starch, hydroxypropyl splash powder, cumyl methyl powder, α-cyclodextrin '/ 3 -Cyclodextrin, 1,3-/ 3 -glucozide, etc.-9- (6) (6) 200303219 Cellulose systems include crystalline cellulose, hydroxypropyl cellulose, and low-substituted hydroxypropyl fibers Cellulose, hydroxypropyl methyl cellulose, carboxymethyl, residual methyl cellulose calcium, sodium carboxymethyl cellulose, croscarmellose sodium and the like. Examples of the polymer substance include synthetic polymer substances such as polyvinyl alkanone and polyvinyl alcohol, and natural polymer substances such as agar gelatin and gelatin. Among these tabletting improvers, the most preferable is a tabletting improver. Corn starch, potato starch, crystalline cellulose, low-substitution hydroxypropyl cellulose, polyethylene ratio alkanone, etc. The equilibrium moisture at a temperature of 25 ° C and a humidity of 12% varies depending on the type of tableting improver. Temperature 25 ° C and humidity 12%. For example, the balanced moisture is about 5.3% of corn starch. 'Potato source flour is about 15%, some alpha starch is 4%, and crystalline fiber is about 2.3 ~ 2.5%. The substituted hydroxypropyl cellulose is about 3.0 to 3.1%, and the polyethylene ratio is about 3.5 to 3.8%. In the present invention, the equilibrium moisture at a temperature of 25 ° C and a humidity of 12% is the moisture in which each compound is placed in a desiccator with a saturated aqueous solution of lithium chloride, and it is left at 25 ° C for 48 hours. The particle size is measured using a volumetric card moisture meter (trade name: KF-〇6, manufactured by Mitsubishi Chemical Co., Ltd.), for example, corn starch is about 2 ~ 3 2 // m, potato starch System is about 7 〇 ~ 9 0 // m, partly α 丨 Dianfen system is about 7 0 # m (average straight), knot -10- (7) (7) 200303219 crystal fiber system is about 1 7 ~ 40 // m Low-substituted hydroxypropyl cellulose is about 25 ~ 50 // m, and polyethylene ratio is 30 ~ 75 / zm. These tableting improvers can be used singly or in combination of two or more. The tableting improvers are usually added in a powder or granular form containing a pharmacologically active substance and a water-soluble excipient. % Or more, preferably 2 to 50% by weight, and more preferably 5 to 20% by weight. The tablets of the present invention are added to a mixture containing a pharmacologically active substance and a water-soluble excipient, and a specific amount of the specific compression improving agent is added, and the additive is then manufactured by a tablet manufacturer. When tableting, a known tableting method can be widely used. Since the device for manufacturing the tablet is a conventional device generally used for preparations of oral preparations, it is not necessary to use a special manufacturing device. The tabletability is improved by the addition of the specific tabletability improver. Therefore, when the tablet is formed, there are no problems such as hindering of tableting, such as covering, and insufficient tablet hardness. As a result, the tablet of the present invention can be manufactured without using a special manufacturing device, and using a general tablet manufacturing device. The tablet of the present invention has sufficient abrasion resistance and mechanical strength, and therefore, it does not cause damage at the time of packaging operation and unsealing of PTP. The tablets of the present invention are intended to be taken by young children and the elderly due to rapid disintegration or dissolution in the oral cavity. [Embodiment] Examples -11-(8) (8) 200303219 Hereinafter, the present invention will be explained more clearly with examples and comparative examples. The details of the tableting improver used below are as follows. Moisture content in various tableting improvers is measured using a volumetric card moisture meter. 0 Corn starch: made by Japan Food Processing Co., Ltd., particle size 2 ~ 3 2 // m, temperature 2 5 ° C , Humidity 12% after storage for 4 8 hours, equilibrium moisture 5.3% potato: made by Nitto Chemical Co., Ltd., particle diameter 70 ~ 90 // m, stored at 25 ° C, humidity 2% 48 After 1 hour, the equilibrium moisture is 1.5%. A Sailu PH — F20 (trade name): crystalline cellulose, manufactured by Asahi Kasei Corporation, average particle diameter 1 7 // m, at temperature 2 5 ° C, humidity 1 2% of the equilibrium moisture after 8 hours of 2.5% Asailu PH — 301 (trade name): crystalline cellulose, manufactured by Asahi Kasei Corporation, average particle diameter 4 0 // m, at temperature 2 5 ° C, Humidity: 12% Equilibrium moisture after storage for 4 8 hours: 2.3% LH-31: Low-substitution hydroxypropyl cellulose, manufactured by Shin-Etsu Chemical Co., Ltd., with an average particle diameter of 2 5 // m. Temperature 2 5 ° C, humidity 12%. Equilibrium moisture after storage for 4 to 8 hours 3.1% LH-1 1: low substitution hydroxyl Based on cellulose, manufactured by Shin-Etsu Chemical Co., Ltd., with an average particle diameter of 50 0 // m, and a temperature of 25 ° C and a humidity of 12% for 48 hours, the equilibrium moisture is 3.0% PVP (XL — 10): Polypropyl than each alkanone made by Japan ISP (Co., Ltd.), average particle diameter 30 millimeters, at temperature 2 5 ° C, humidity] 2% -12- 200303219 〇) After storage for 4 8 hours Equilibrium moisture: 5.8% PVP (XL): made of polypropyl acetone, manufactured by Japan ISP (Co., Ltd.), average particle diameter 7 5 // m, stored at temperature 2 5 ° C, humidity 12%, stored for 4 8 hours Equilibrium moisture at the rear 3.5% Fuki Carin SG (trade name): Calcium phosphate, manufactured by Fuji Chemical Industry Co., Ltd., average particle diameter 1 13 // m, stored at 25 ° C and 12% humidity After 48 hours, the equilibrium moisture content was 0.9%. Car B was processed (heated to 80 ° C. for more than 3 hours in a vacuum) and the various tableting improvers were prepared to obtain adjusted product A. In addition, a humidification treatment (stored at a temperature of 25 ° C and a humidity of 60% for 24 hours or more) of these various tabletability improving agents was used to prepare an adjusted product D. The adjustment product A and the adjustment product D were mixed to obtain an adjustment product B and an adjustment product c. The moisture content of these adjusted products is shown in Table 1.

•13- (10) 200303219 表1 (3)之改善劑 調整後之水份(% ) 調整品A 調整品B 調整品C 調整品D 玉米澱粉 3.0 6.1 9.1 13.5 馬鈴薯澱粉 0.7 9.2 阿比賽魯PH- F20 1.7 2.7 6.2 8.3 阿比賽魯PH- 301 1.2 6.7 LH- 3 1 1.2 4.0 7.9 10.5 LH- 1 1 0.8 6.5 P VP(XL- 10) 1.7 18.7 PVP(XL) 0.9 6.1 11.3 18.5 富基卡林S G (商品名) 0.6 2.5• 13- (10) 200303219 Table 1 (3) Adjusted water content (%) Modifier A Modifier B Modifier C Modifier D Corn starch 3.0 6.1 9.1 13.5 Potato starch 0.7 9.2 Asailu PH- F20 1.7 2.7 6.2 8.3 Asailu PH- 301 1.2 6.7 LH- 3 1 1.2 4.0 7.9 10.5 LH- 1 1 0.8 6.5 P VP (XL-10) 1.7 18.7 PVP (XL) 0.9 6.1 11.3 18.5 Fuki Carin SG (Commodity First name) 0.6 2.5

打錬試驗1 調製下述表2所示之以糖醇爲基質之顆粒(處方1〜3 ) 。各顆粒之造粒係經由使用馬魯器普雷庫司MP - 0 1 (商品 名)(P 0 W R E X公司製作)之攪拌流動造粒法而進行。 -14- (11) 200303219 表2 處方1 處方2 處方3 赤蘚醇(m g) 147 甘露糖醇(mg) 147 木糖醇(m g) 147 HPC- L(mg) 3 3 3 合計(m g ) 1 50 1 50 1 50 HPC-L:日本曹達(有限公司)製作 處方例1之顆粒規格係1 3 3 // m、處方2之顆粒規格 係102/zm、處方3之顆粒規格係299//m。 對於處方1〜3之顆粒,添加潤滑劑(硬酯酸鎂、太平 化學產業(股份有限公司)製作)〇.5重量%,且使用打錠機 (12HUK、菊水製作所(股份有限公司)製作)以打錠壓 1 0 0 0 K g打淀。打錠時,使用直徑8 m m、隙角R之杵桿。 調查打錠時之打錠性(是否產生覆蓋物、減壓上昇或 雜音增大)。將添加有硬酯酸鎂之混合物打錠爲處方1之 顆粒時,確認覆蓋物之產生。將添加硬酯酸鎂之混合物打 錠爲處方2或處方3之顆粒時,確認減壓上昇及雜音增大 。由此些結果得知,任一混合物打錠性爲不佳。 對於處方1〜3之顆粒,添加調整品A〜D 1 0重量% 。又,對於調整品A〜D添加後之顆粒混合物,添加潤滑 劑(硬酯酸鎂、太平化學產業(股份有限公司)製作)〇.5重量 %。將所得之混合物使用打錠機(1 2HUK '菊水製作所(股 -15- 200303219 (12) 份有限公司)製作),以打錠壓1 000kg打錠。打錠時,使 用直徑8 m m、隙角R之杵桿。 調查打錠時之打錠性(是否產生覆蓋物、減壓上昇或 雜音增大)。對於處方1〜3之顆粒,與添加潤滑劑(硬酯 酸鎂、太平化學產業(股份有限公司)製作)0.5重量%之混 合物比較,無法完全認定打錠阻礙(是否產生覆蓋物、減 壓上昇或雜音增大)之改善或惡化時爲X ,可認定打旋阻 礙(是否產生覆蓋物、減壓上昇或雜音增大)之改善或幾乎 不產生打錠阻礙時爲〇’完全不產生打錠阻礙(是否產生 覆蓋物、減壓上昇或雜音增大)時,可判定爲◎。其結果 表示如表3及表4。 (13)200303219 表3Snoring test 1 Prepare sugar alcohol-based particles (prescriptions 1 to 3) shown in Table 2 below. The granulation of each pellet was carried out by a stirring flow granulation method using a Marubeni Precus MP-01 (trade name) (produced by P 0 W R E X). -14- (11) 200303219 Table 2 Formula 1 Formula 2 Formula 3 Erythritol (mg) 147 Mannitol (mg) 147 Xylitol (mg) 147 HPC- L (mg) 3 3 3 Total (mg) 1 50 1 50 1 50 HPC-L: Japan Cao Da (Co., Ltd.) made the particle size of Formula 1 1 3 3 // m, the particle size of Formula 2 was 102 / zm, and the particle size of Formula 3 was 299 // m . For the granules of prescriptions 1 to 3, add 0.5% by weight of lubricant (magnesium stearate, manufactured by Taiping Chemical Industry Co., Ltd.), and use a tableting machine (12HUK, manufactured by Kikusui Manufacturing Co., Ltd.) Press the ingot to press 1 0 0 0 0 g g. When punching, use a pestle rod with a diameter of 8 mm and a clearance angle of R. Investigate the injectability of the ingots (whether there is a covering, increased decompression, or increased noise). When the mixture to which magnesium stearate was added was granulated into granules of Formula 1, the generation of the covering was confirmed. When the mixture containing magnesium stearate was granulated into the granules of Formula 2 or Formula 3, it was confirmed that the decompression increased and the noise increased. From these results, it has been found that the spindle properties of any mixture are not good. For granules of prescriptions 1 to 3, adjusters A to D 10 are added at 10% by weight. In addition, a lubricant (magnesium stearate, manufactured by Taiping Chemical Industry Co., Ltd.) was added to the granular mixture after the adjustment products A to D were added by 0.5% by weight. The obtained mixture was beaten with a tableting machine (made by 12HUK 'Kikusui Seisakusho Co., Ltd. (15-200303219 (12) Co., Ltd.)), and pressed at a rate of 1,000 kg. When punching, use a pestle rod with a diameter of 8 mm and a clearance angle of R. Investigate the injectability of the ingots (whether there is a covering, increased decompression, or increased noise). Regarding the granules of prescriptions 1 to 3, compared with the 0.5% by weight mixture of added lubricant (magnesium stearate, manufactured by Taiping Chemical Industry Co., Ltd.), it is impossible to fully identify the impediment of the tableting (whether there is a covering or an increase in decompression). Or increase in noise) is X when it is improved or deteriorated, it can be considered that the improvement of swirling resistance (whether a cover is generated, decompression increase or noise increase) or there is almost no spindle resistance is 0 '. If it is obstructed (whether a cover is generated, the pressure is reduced, or the noise is increased), it can be judged as ◎. The results are shown in Tables 3 and 4. (13) 200303219 Table 3

處方3 (3 )之改善劑 調整品 打錠性 玉米澱粉 A X B 〇 C ◎ D ◎ 馬鈴薯澱粉 A X D 〇 阿比賽魯 A X PH- F20 B ◎ D ◎ 阿比賽魯 A X PH- 301 D ◎ LH- 3 1 A X B ◎ D ◎ LH- 1 1 A X D ◎ P VP(XL- 10) A X D ◎ PVP(XL) A X B 〇 C ◎ D ◎ 富基卡林S G A X (商品名) D XImprover for prescription 3 (3) Modified product of corn starch AXB 〇C ◎ D ◎ Potato starch AXD 〇 Asailu AX PH- F20 B ◎ D ◎ Asailu AX PH- 301 D ◎ LH- 3 1 AXB ◎ D ◎ LH- 1 1 AXD ◎ P VP (XL-10) AXD ◎ PVP (XL) AXB 〇C ◎ D ◎ Fuki Carin SGAX (brand name) DX

-17- (14) 200303219 表4-17- (14) 200303219 Table 4

(3 )之改善劑 調整品 處方1 處方 2 打錠性 打錠性 王米澱粉 A X X B ο 〇 C 〇 ◎ D ◎ ◎ PVP ( XL ) A X X B 〇 〇 D ◎ ◎ 富基卡林 A X X D X X(3) Improver Modifiers Prescriptions 1 Prescriptions 2 Tableting properties Tableting properties King rice starch A X X B ο 〇 C 〇 ◎ D ◎ ◎ PVP (XL) A X X B 〇 〇 D ◎ ◎ Fuki Carin A X X D X X

雖然含有於溫度25°C,溼度12%保存48小時後之平 均水份,但平均粒子徑係超過100/zm之富基卡林SG(商 品名)係不可改善打錠時之壓片性,由表3及表4可得知 打錠試驗2 調製下述所示之處方之以糖醇作爲基質的頼粒。顆粒 之造粒係經由使用馬魯器普雷庫司Μ P — 〇 1 (Ρ Ο W R E X公 司製作)之攪拌流動造粒法而進行。 顆粒之處方4 : •18- (15) (15)200303219 赤蘚醇 1 1 7重量部 玉米粉 3 0重量部 HPC- L 3重量部 處方4之顆粒規格係1 6 // m。 對於處方4之顆粒,添加潤滑劑(硬酯酸鎂、太平化 學產業(股份有限公司)製作)0.5重量%,使用打錠機 (12HUK、菊水製作所(股份有限公司)製作),以打錠壓 1 0 0 0 k g打錠。打錠係使用直徑8 m m、隙角R之杵桿。 調查打錠時之打錠性(是否產生覆蓋物、減壓上昇或 雜音增大)。 對於該處方之顆粒打錠添加硬酯酸鎂之混合物時,可 確認覆蓋物之產生。 對於處方4之顆粒,添加玉米澱粉(調整品 A〜D) 10 重量%。再對於調整品 A〜D添加後之顆粒混合物,添 加潤滑劑(硬酯酸鎂、太平化學產業(股份有限公司)製作 )0.5重量%。將製得之混合物使用打錠機U2HUK、菊水 製作所(股份有限公司)製作)以打錠壓1 00 0kg打錠。打錠 係使用直徑Smm、隙角R之杵桿。 調查與打錠試驗1相同之方法及加以判定打錠時之打 錠性(是否產生覆蓋物' 減壓上昇或雜音增大)° 於處方4之顆粒中’添加調整品A之混合物的判定 係X ,於處方4之顆粒’添加調整品B之混合物的判定係 〇’於處方4之顆粒中’添加胃周整品1 C之混合物β的判足 係◎,添加調整品D之混合物之的判定係◎ ° -19- (16) (16)200303219 打錠試驗3 對於處方4之顆粒(打錠試驗),添加玉米澱粉(調整 品)5重量%或10重量%。再對於調整品D添加後之顆粒 混合物,添加潤滑劑(硬酯酸鎂、太平化學產業(股份有限 公司)製作)〇.5重量%。將所得之混合物使用打錠機 (12HUK、菊水製作所(股份有限公司)製作)以打錠壓 1 000kg打錠。打錠係使用直徑8mm、隙角R之杵桿。 與其比較,即使不添加玉米澱粉(調整品D),亦以相 同知打錠壓l〇〇〇kg打錠。 測定所製得之各片劑之平均重量(mg)、平均硬度(kp) 及平均厚度(mm)。 平均重量(mg)係片劑1 〇錠之平均重量。 平均硬度(k p)係使用片劑硬度計(模型6 d、雪絡尼克 魯公司製作),測定片劑5錠之硬度且平均者。 平均厚度(mm)係使用厚度計(模型g、PEACOCK公司 製作),測定片劑5錠之厚度,且平均者。 又’將所得之各片劑供給於崩解試驗。崩解試驗係使 用崩解試驗器(模型NF - 2F、富山產業(股份有限公司)製 作)’依據日本藥局(1 4局修正)進行。 於各片劑之口腔內之崩解時間(秒)係片劑2個之平均 値。 調查與打錠試驗1相同方法及判定之打錠時之打錠性 (是否產生覆蓋物)。 -20- (17)200303219 其結果表示如表5。 表5 (3)之改善劑添加量 0% 5% 10% 打錠壓(kg) 1000 1000 1000 平均重量(mg) 150.4 158.2 168.9 平均硬度(kp) 3.5 5.3 5.8 平均厚度(mm) 2.96 3.06 3.22 崩壞時間(秒) 22 〜28 20 〜30 23 〜41 口腔內崩壞時間(秒) 18 19 19 產生覆蓋物 有 >6τΤ. Μ 不添加玉米澱粉(調整品D)係可確認覆蓋物之產生 ,但經由添加玉米澱粉(調整品D)5重量%,可完全防止 覆蓋物之產生。又,配合玉米澱粉之添加量可確認片劑硬 度之上昇。關於崩解性,不添加玉米澱粉(調整品D)時與 添加玉米澱粉(調整品D)5重量%時係相同程度。 經由添加玉米澱粉(調整品D) 1 0重量%之崩解試驗的 崩解性稍微降低,而口腔內崩解中’不添加玉米灑粉(調 整品D)及5重量%時,無法確認差異。 打錠試驗4 以下述表6之處方使用與打錠試驗1相同之方法製造 片劑 -21 - (18) 200303219 使用與打錠試驗3之方法,測定所製得之各片劑之 平均重量(mg)、平均厚度(mm)、平均硬度(kp)及朋解時間 (秒)。 摩損度(% )係使用摩損度試驗器(模型TF T - 1 2 0、 富山產業(股份有限公司)製作),且回轉數25rpm、15分 鐘後之片劑(2 〇片)的摩損度。 又,調查與打錠試驗1相同之方法% &及_定打錠時之打Although it contains the average water content after 48 hours of storage at a temperature of 25 ° C and a humidity of 12%, the Fukikalin SG (trade name) with an average particle diameter of more than 100 / zm cannot improve the tableting properties when ingoting. Tables 3 and 4 show that the tableting test 2 prepared the granules using sugar alcohol as a base in the following manner. The granulation of the granules was performed by a stirring flow granulation method using a Marubeni Precus Mp — 〇1 (manufactured by P W RW E X Corporation). Granule formula 4: • 18- (15) (15) 200303219 Erythritol 1 1 7 weight part Corn flour 3 0 weight part HPC- L 3 weight part The particle size of prescription 4 is 16 / m. For the granules of Formula 4, 0.5% by weight of lubricant (magnesium stearate, manufactured by Taiping Chemical Industry Co., Ltd.) was added, and a tableting machine (12HUK, manufactured by Kikusui Manufacturing Co., Ltd.) was used for tabletting. 1 0 0 0 kg ingot. The ingot-making system uses a rod with a diameter of 8 mm and a clearance angle of R. Investigate the injectability of the ingots (whether there is a covering, increased decompression, or increased noise). When a mixture of magnesium stearate was added to the granulated tablets of the prescription, generation of a covering was confirmed. For the granules of Formula 4, corn starch (adjustments A to D) was added at 10% by weight. To the granulated mixture after the adjustments A to D were added, a lubricant (magnesium stearate, manufactured by Taiping Chemical Industry Co., Ltd.) was added in an amount of 0.5% by weight. The obtained mixture was pressed with a tableting machine U2HUK and Kikusui Manufacturing Co., Ltd. to produce a 1000 kg tablet. The ingots are punched with a diameter of Smm and a clearance angle of R. Investigate the same method as ingot injecting test 1 and determine the injectability (increase of depressurization or increase of noise) when injecting industy ° Determination of the mixture of "adjustment A" added to the granules of prescription 4 X, the determination of the mixture of the adjustment product B added to the granule of prescription 4 is the determination of the foot system of the mixture of the whole stomach 1 C added to the granule of the prescription 4, and the addition of the mixture of adjustment D Judgment ◎ ° -19- (16) (16) 200303219 Ingot Test 3 For the pellets (inject test) of Formula 4, corn starch (adjustment) was added at 5% or 10% by weight. To the granulated mixture after the adjustment product D was added, a lubricant (magnesium stearate, manufactured by Taiping Chemical Industry Co., Ltd.) was added at 0.5% by weight. The obtained mixture was pressed with a tableting machine (12HUK, manufactured by Kikusui Seisakusho Co., Ltd.) at a rate of 1 000 kg. The ingot was punched with a pestle rod having a diameter of 8 mm and a clearance angle of R. In comparison, even if corn starch (adjustment D) was not added, the same known tableting pressure was used to beat 1000 kg of tableting. The average weight (mg), average hardness (kp), and average thickness (mm) of each of the obtained tablets were measured. The average weight (mg) is the average weight of 10 tablets. The average hardness (k p) was measured using a tablet hardness tester (model 6 d, manufactured by Xueluo Niklu), and the average hardness was measured for 5 tablets. The average thickness (mm) was measured using a thickness gauge (model g, manufactured by PEACOCK), and the thickness of 5 tablets was averaged. Each of the obtained tablets was subjected to a disintegration test. The disintegration test is performed using a disintegration tester (model NF-2F, manufactured by Toyama Industry Co., Ltd.) 'in accordance with the Japan Pharmacy (14 Bureau amendments). The disintegration time (seconds) in the oral cavity of each tablet is the average of 2 tablets. Investigate the injectability (injection of cover) during injecting by the same method and judgement as in injecting test 1. -20- (17) 200303219 The results are shown in Table 5. Table 5 (3) Additive content of 0% 5% 10% Ingot pressing pressure (kg) 1000 1000 1000 Average weight (mg) 150.4 158.2 168.9 Average hardness (kp) 3.5 5.3 5.8 Average thickness (mm) 2.96 3.06 3.22 Collapse Bad time (seconds) 22 ~ 28 20 ~ 30 23 ~ 41 Oral disintegration time (seconds) 18 19 19 Cover generation > 6τΤ. Μ No addition of corn starch (adjustment D) can confirm the production of the cover However, by adding 5% by weight of corn starch (adjustment D), the production of coverings can be completely prevented. In addition, an increase in the hardness of the tablet was confirmed by the amount of corn starch added. Regarding disintegration, when corn starch (adjustment D) is not added, it is about the same as when corn starch (adjustment D) is added at 5% by weight. The disintegration was slightly reduced by the disintegration test of 10% by weight of corn starch (adjustment D), and the difference was not confirmed when no corn flour (adjustment D) and 5% by weight were added during oral disintegration. . Tableting test 4 Tablets 21-(18) 200303219 were manufactured in the same manner as in tableting test 1 in the following Table 6 using the method of tableting test 3 to determine the average weight of each tablet ( mg), average thickness (mm), average hardness (kp), and solution time (seconds). The abrasion degree (%) is the abrasion degree of a tablet (20 pieces) after a rotation speed of 25 rpm and a rotation speed of 25 rpm using a friction tester (model TF T-120, manufactured by Toyama Industry Co., Ltd.). In addition, the same method as that of the ingot test 1 was investigated.

錠性(是否覆蓋物之產生)。其結果表示% _ 6Pastilleness (whether the cover is produced). The result shows% _ 6

-22- (19)200303219 表6 處方5 處方6 處方7 aripiprazol(mg) 15 15 15 赤蘚醇(mg) 102 1 02 102 玉米澱粉(mg) 3 0 3 0 30 HPC- L 3 3 3 (3)改善劑玉米澱粉(mg) 15 PCS (mg) 7.5 PVP(XL)(mg) 7.5 硬酯酸鎂 (mg) 0.8 0.8 0.8 合計 (mg) 165.8 15 8.3 158.3 打錠壓(kg) 600 600 600 平均重量(mg) 166.3 157.8 157.4 平均厚度(mm) 3.25 3.14 3.18 平均硬度(kp) 3.3 3.4 3.7 崩壞時間(水)(分 ) 24 〜29 25 〜30 1 5 〜20 壓片性 良好 良好 良好 玉米澱粉之水分 :13.5% P C S之水分:1 2 . .3% PVP(XL)之水分: 1 8.5 % -23- (20) (20)200303219 打錠試驗5 以下述表7之處方’使用與打錠試驗1相同之方法製 造片劑。 使用與打錠試驗3之相同方法測定所製得之各片劑之 平均重量(mg)、平均厚度(mm)、平均硬度(kp)及崩解時間 (秒)。 摩損度(%)係使用與打錠試驗4相同之方法測定。 又,調查與打錠試驗1相同之方法及判定打錠時之打 錠性(是否產生覆蓋物)。 其結果表示如表7。 -24· (21) (21)200303219 表7 處方8 處方9 處方10 處方11 藥理活性物質A (mg) 15 15 藥理活性物質B (mg) 15 15 赤蘚醇 (mg) 102 102 102 102 玉米澱粉 (mg) 30 30 30 30 HPC-L (mg) 3 3 3 3 (3)改善劑玉米澱粉(mg) 15 15 PVP(XL)(mg) 7.5 7.5 硬酯酸鎂 (mg) 0.8 0.8 0.8 0.8 合計(mg) 165.8 158.3 158.3 158.3 打錠壓(kg) 800 800 600 600 平均重量(mg) 165.5 158.4 168.1 157.6 平均厚度(mm) 3.18 3.14 3.33 3.23 平均硬度(kp) 3.7 3.9 3.7 3.4 崩壞時間(水)(分) 24 〜35 21 〜23 35 〜40 25 〜28 磨損度(%) 0.7 0.3 1.4 1.0 壓片性 良好 良好 良好 良好 玉米澱粉之水分:1 3 . 5 % PVP(XL)之水分:18.5% -25- (22) (22)200303219 關於表7之藥理活性物質a係i 一〔 3 一 { 4〜(3〜 氯苯)—1—比秦烷基丨丙基一 5 -甲氧一 3,4 一二氫化〜 2 (1 H)-奎林單甲烷磺酸酯。 又,藥理活性物質B係(5 R)〜2 -〔 1 — { 2 —氯代〜$ 一 (Ϊ —比各完基)苯醯丨—2,3,4,5 -四氫化〜lH—b 苄丫庚因—5 -基〕一 N-異丙基乙醯胺基。 打錠試驗6 以下述表8所示之處方,使用與打錠試驗1相同方法 製造片劑。 使用與打細§式驗3之相R方法,測定所製得之各片劑 之平均重量(mg)、平均厚度(mm)、平均硬度(kp)及崩解時 間(秒)。 又,調查與打錠試驗1相同之方法及判定打錠時之打 錠性(是否產生覆蓋物)。 其結果表示如表8。 -26- (23)200303219 表8 處方12 處方13 西洛他11坐片(cilostazol) (mg) 50 50 赤蘚醇 (mg) 146 48 HPC- L 4 2 (3)改善劑 PVP(XL) (mg) 10 5 硬酯酸鎂 (mg) 1.1 0.5 合計 (mg) 211.1 105.5 杵桿之形狀 直徑10.5mm隙角R 直徑7mm,糖衣R(5.5R) 打錠壓(kg) 600 300 平均重量(mg) 212.9 105.3 平均厚度(mm) 3.16 3.58 平均硬度(kp) 4.3 5.6 崩壞時間(水)(分) 15 〜20 20 〜25 壓片性 良好 良好 PVP(XL)之水分: 1 8.5 %-22- (19) 200303219 Table 6 Prescription 5 Prescription 6 Prescription 7 aripiprazol (mg) 15 15 15 Erythritol (mg) 102 1 02 102 Corn starch (mg) 3 0 3 0 30 HPC- L 3 3 3 (3 ) Improver Corn starch (mg) 15 PCS (mg) 7.5 PVP (XL) (mg) 7.5 Magnesium stearate (mg) 0.8 0.8 0.8 Total (mg) 165.8 15 8.3 158.3 Tablet pressure (kg) 600 600 600 Average Weight (mg) 166.3 157.8 157.4 Average thickness (mm) 3.25 3.14 3.18 Average hardness (kp) 3.3 3.4 3.7 Crash time (water) (minutes) 24 ~ 29 25 ~ 30 1 5 ~ 20 Good tabletability Good good corn starch Water content: 13.5% PCS water content: 1 2. .3% PVP (XL) water content: 1 8.5% -23- (20) (20) 200303219 Ingot test 5 Use the following table 7 for 'use and ingot Tablets were produced in the same manner as in Test 1. The average weight (mg), average thickness (mm), average hardness (kp), and disintegration time (seconds) of each of the tablets obtained were measured in the same manner as in the tableting test 3. The degree of abrasion (%) was measured by the same method as in the ingot test 4. In addition, the same method as that of the ingot test 1 and the determination of the injectability (whether a cover was generated) during ingot ingotting were investigated. The results are shown in Table 7. -24 · (21) (21) 200303219 Table 7 Formula 8 Formula 9 Formula 10 Formula 11 Pharmacologically active substance A (mg) 15 15 Pharmacologically active substance B (mg) 15 15 Erythritol (mg) 102 102 102 102 Corn starch (mg) 30 30 30 30 HPC-L (mg) 3 3 3 3 (3) Improver corn starch (mg) 15 15 PVP (XL) (mg) 7.5 7.5 magnesium stearate (mg) 0.8 0.8 0.8 0.8 Total (Mg) 165.8 158.3 158.3 158.3 Ingot pressure (kg) 800 800 600 600 Average weight (mg) 165.5 158.4 168.1 157.6 Average thickness (mm) 3.18 3.14 3.33 3.23 Average hardness (kp) 3.7 3.9 3.7 3.4 Crash time (water) (Minutes) 24 ~ 35 21 ~ 23 35 ~ 40 25 ~ 28 Abrasion (%) 0.7 0.3 1.4 1.0 Good tabletability Good Good Moisture of corn starch: 1 3.5% Moisture of PVP (XL): 18.5% -25- (22) (22) 200303219 About the pharmacologically active substance a of Table 7 i- [3-{4 ~ (3 ~ chlorobenzene) — 1- than Qinyl 丨 propyl 5-methoxy 3 , 4 Dihydrogen ~ 2 (1 H) -Quulin monomethane sulfonate. In addition, the pharmacologically active substance B is (5 R) ~ 2-[1 — {2 —chloro ~ $ one (一 — than each end) benzene 醯 丨-2, 3, 4, 5-tetrahydro ~ 1H- b Benzylidene-5-yl] -N-isopropylacetamido. Tableting test 6 Tablets were produced in the same manner as in the tableting test 1 using the method shown in Table 8 below. Using the phase R method with the fine test § 3, the average weight (mg), average thickness (mm), average hardness (kp), and disintegration time (seconds) of each tablet produced were measured. In addition, the same method as that of the ingot test 1 and the determination of the injectability (whether a cover was generated) during ingot ingotting were investigated. The results are shown in Table 8. -26- (23) 200303219 Table 8 Prescription 12 Prescription 13 Cilostazol 11 (cilostazol) (mg) 50 50 Erythritol (mg) 146 48 HPC- L 4 2 (3) Improver PVP (XL) ( mg) 10 5 Magnesium stearate (mg) 1.1 0.5 Total (mg) 211.1 105.5 Shape of pestle rod diameter 10.5mm clearance angle R diameter 7mm, sugar-coated R (5.5R) tablet pressure (kg) 600 300 average weight (mg ) 212.9 105.3 Average thickness (mm) 3.16 3.58 Average hardness (kp) 4.3 5.6 Crash time (water) (minutes) 15 ~ 20 20 ~ 25 Good tabletability Good moisture content of PVP (XL): 1 8.5%

-27--27-

Claims (1)

(1) (1)200303219 拾、申請專利範圍 1 . 一種片劑’其特徵爲於含有(n )有效量之藥理活性物 質及(2)50重量%以上之水溶性賦形劑之粉狀或顆粒狀混 合物中,將(3)具有溫度2VC、溼度12%之平衡水份以上 之水份,且平均粒徑1 00 // m以下之壓片性改善劑,對於 該混合物以1〜5 0重量%之比例添加且壓片製得。 2.—種片劑之製造方法,其特徵爲於含有(1)有效量之 藥理活性物質及(2)50重量%以上之水溶性賦形劑之粉狀 或顆粒狀混合物中,將(3)具有溫度25 °C、溼度I2%之平 衡水份以上之水份,且平均粒徑1 0 0 // m以下之壓片性改 善劑,對於該混合物以1〜5 0重量%之比例添加且壓片者 -28-(1) (1) 200303219, patent application scope 1. A tablet 'characterized by a powder or containing a (n) effective amount of a pharmacologically active substance and (2) a water-soluble excipient of 50% by weight or more In the granular mixture, (3) a tableting improver having a moisture content of 2VC or higher and a moisture balance of 12% or more and an average particle diameter of 100 / m or less, and 1 to 50 for the mixture It is added in the proportion of% by weight and tabletted. 2. A method for manufacturing a tablet, characterized in that (3) a powdery or granular mixture containing (1) an effective amount of a pharmacologically active substance and (2) 50% by weight or more of a water-soluble excipient, ) A tabletting improver with a moisture content of 25 ° C or more and an equilibrium moisture content of I2% and an average particle size of 1 0 0 // m or less, added to the mixture in a proportion of 1 to 50% by weight And tablet player-28-
TW092102910A 2002-02-15 2003-02-12 Tablets having improved tabletting characteristics and process for producing the same TW200303219A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002038014A JP2003238393A (en) 2002-02-15 2002-02-15 Tablet with improved tableting property and method for producing the same

Publications (1)

Publication Number Publication Date
TW200303219A true TW200303219A (en) 2003-09-01

Family

ID=27678145

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092102910A TW200303219A (en) 2002-02-15 2003-02-12 Tablets having improved tabletting characteristics and process for producing the same

Country Status (9)

Country Link
US (1) US20050089557A1 (en)
EP (1) EP1475084A1 (en)
JP (1) JP2003238393A (en)
KR (1) KR100661782B1 (en)
CN (1) CN1321629C (en)
CA (1) CA2473569A1 (en)
MX (1) MXPA04007812A (en)
TW (1) TW200303219A (en)
WO (1) WO2003068194A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033485A1 (en) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd MEDICINAL SUBSTANCE OF ARIPIPRAZOL OF LOW HYGROSCOPICITY AND PROCESS FOR THE PREPARATION OF THE SAME
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
JP2006176496A (en) * 2004-11-24 2006-07-06 Freunt Ind Co Ltd Solid agent and process for producing the same
TWI383809B (en) * 2005-06-29 2013-02-01 Otsuka Pharma Co Ltd Orally disintegrating powder comprising cilostazol
WO2007081366A1 (en) * 2006-01-05 2007-07-19 Teva Pharmaceutical Industries Ltd. Wet granulation pharmaceutical compositions of aripiprazole
PL1808165T3 (en) * 2006-01-05 2009-09-30 Teva Pharma Dry formulations of aripiprazole
CN101322709B (en) * 2007-06-12 2011-03-02 成都康弘药业集团股份有限公司 Medicament composition containing aripiprazole and preparation thereof
JOP20200109A1 (en) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd Injectable preparation
JP2016204260A (en) * 2013-10-04 2016-12-08 日本曹達株式会社 Production method of tablet
CN114146061B (en) * 2020-09-07 2023-06-30 歌礼生物科技(杭州)有限公司 Protease inhibitor synergistic composition containing solid dispersion and preparation method thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2064564T3 (en) * 1989-09-21 1995-02-01 American Cyanamid Co PULSE PRESSURE RELEASE SYSTEM OF DAILY UNIT DOSE OF MINOCYCLINE.
JP3069458B2 (en) * 1992-01-29 2000-07-24 武田薬品工業株式会社 Orally disintegrating tablet and production method thereof
JPH06218028A (en) * 1992-10-02 1994-08-09 Eisai Co Ltd Method and apparatus for molding wet-processed tablet, and the wet-processed tablet
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
JP2919771B2 (en) * 1995-04-17 1999-07-19 佐藤製薬株式会社 Method for producing fast-dissolving tablet and fast-dissolving tablet produced by the method
US6057139A (en) * 1995-06-29 2000-05-02 Mcneil-Ppc, Inc. Preblend of microcrystalline cellulose and lactase for making tablets
JPH0948726A (en) * 1995-08-07 1997-02-18 Tanabe Seiyaku Co Ltd Rapidly disintegrating preparation in mouth cavity and its production
AU733032C (en) * 1996-06-14 2002-01-03 Kyowa Hakko Kirin Co., Ltd. Intraorally rapidly disintegrable tablet
KR20050071718A (en) * 1996-07-12 2005-07-07 다이이찌 세이야꾸 가부시기가이샤 Quickly disintegratable compression-molded materials and process for producing the same
EP0839526A3 (en) * 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
JPH10298062A (en) * 1997-04-24 1998-11-10 Pfizer Pharmaceut Co Ltd Rapidly dissolving type tablet in oral cavity
JP3182404B2 (en) * 1998-01-14 2001-07-03 大日本製薬株式会社 Orally disintegrating tablet and method for producing the same
WO1999043306A1 (en) * 1998-02-26 1999-09-02 Banyu Pharmaceutical Co., Ltd. An orally disintegrating composition and its manufacturing method
JPH11302157A (en) * 1998-04-17 1999-11-02 Eisai Co Ltd Tablet quickly disintegrating in oral cavity
ES2237121T3 (en) * 1998-07-28 2005-07-16 Takeda Pharmaceutical Company Limited FAST DISGREGABLE SOLID PREPARATION.
ATE400426T1 (en) * 1999-01-29 2008-07-15 Takeda Pharmaceutical COMPACTION HAMMER WITH COATING TREATMENT
JP4249847B2 (en) * 1999-05-31 2009-04-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 Orally disintegrating tablets containing vitamin K
WO2000078292A1 (en) * 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
US7727548B2 (en) * 2000-03-01 2010-06-01 Eisai R&D Management Co., Ltd. Rapidly disintegrable tablet containing polyvinyl alcohol
JP4162405B2 (en) * 2000-12-28 2008-10-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 Mold lock
WO2002092058A1 (en) * 2001-05-15 2002-11-21 Takeda Chemical Industries, Ltd. Rapidly disintegratable solid preparation

Also Published As

Publication number Publication date
EP1475084A1 (en) 2004-11-10
KR100661782B1 (en) 2006-12-28
AU2003211956A1 (en) 2003-09-04
CN1321629C (en) 2007-06-20
US20050089557A1 (en) 2005-04-28
WO2003068194A1 (en) 2003-08-21
CA2473569A1 (en) 2003-08-21
MXPA04007812A (en) 2004-10-15
JP2003238393A (en) 2003-08-27
KR20040083500A (en) 2004-10-02
CN1658843A (en) 2005-08-24

Similar Documents

Publication Publication Date Title
EP2218443B1 (en) Orally disintegrating tablet
JP5366233B2 (en) Orally disintegrating tablets
JP5332615B2 (en) Orally disintegrating tablet and method for producing the same
CA2374760A1 (en) Quickly disintegrating solid preparations
CN106913553A (en) Oral disnitegration tablet and its manufacture method
JP5342028B2 (en) Orally disintegrating tablets
TWI733650B (en) Disintegrable particle composition containing microfibrous cellulose
JP5610865B2 (en) Solid preparation
JP2000273039A (en) Composition disintegrable in oral cavity
CN104159583A (en) Solid pharmaceutical composition containing 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof
TW200303219A (en) Tablets having improved tabletting characteristics and process for producing the same
JP2009513530A5 (en)
TW550082B (en) Disintegrant
EP1944017A2 (en) Rapidly disintegrating tablet in the oral cavity
WO2012091049A1 (en) Orally disintegrating tablet
JP6762898B2 (en) Orally disintegrating tablets containing galantamine hydrobromic acid
JP5549443B2 (en) Orally disintegrating tablet and method for producing the same
WO2010119851A1 (en) Orally disintegrating tablet
JP4562797B1 (en) Orally disintegrating tablets containing precipitated calcium carbonate as an active ingredient
TWI637749B (en) Disintegrating particle composition produced in two-stage wet granulation step and oral disintegrating tablet containing the composition
JP2002138055A (en) Intraoral quick disintegration type compression molding and its production method
JP6407084B2 (en) Tablet and production method thereof
JP2005298338A (en) Quickly disintegrating compression-molded preparation
JP6651638B2 (en) Orally disintegrating tablet additive composition
US20230201123A1 (en) Pharmaceutical composition